These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 11574189

  • 1. Advanced-generation macrolides: tissue-directed antibiotics.
    Amsden GW.
    Int J Antimicrob Agents; 2001; 18 Suppl 1():S11-5. PubMed ID: 11574189
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Review of macrolides and ketolides: focus on respiratory tract infections.
    Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, Karlowsky JA.
    Drugs; 2001; 61(4):443-98. PubMed ID: 11324679
    [Abstract] [Full Text] [Related]

  • 5. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.
    Dunn CJ, Barradell LB.
    Drugs; 1996 Mar; 51(3):483-505. PubMed ID: 8882383
    [Abstract] [Full Text] [Related]

  • 6. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.
    Carbon C, Poole MD.
    J Chemother; 1999 Apr; 11(2):107-18. PubMed ID: 10326741
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Azithromycin and clarithromycin: overview and comparison with erythromycin.
    Whitman MS, Tunkel AR.
    Infect Control Hosp Epidemiol; 1992 Jun; 13(6):357-68. PubMed ID: 1320067
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The macrolides: erythromycin, clarithromycin, and azithromycin.
    Alvarez-Elcoro S, Enzler MJ.
    Mayo Clin Proc; 1999 Jun; 74(6):613-34. PubMed ID: 10377939
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Azithromycin--review of key chemical, pharmacokinetic and microbiological features.
    Lode H, Borner K, Koeppe P, Schaberg T.
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():1-8. PubMed ID: 8818841
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [In vitro and in vivo antibacterial activities of azithromycin].
    Miyazaki S, Yamaguchi K.
    Jpn J Antibiot; 2000 Jun; 53 Suppl B():22-42. PubMed ID: 12572087
    [Abstract] [Full Text] [Related]

  • 17. In-vitro activity of dirithromycin in comparison with other new and established macrolides.
    Bauernfeind A.
    J Antimicrob Chemother; 1993 Mar; 31 Suppl C():39-49. PubMed ID: 8478311
    [Abstract] [Full Text] [Related]

  • 18. [New macrolides].
    Portier H, Buisson M, Chavanet P.
    Rev Prat; 1994 Jun 15; 44(12):1629-34. PubMed ID: 7939238
    [Abstract] [Full Text] [Related]

  • 19. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ, Zhanel GG.
    Expert Rev Anti Infect Ther; 2006 Dec 15; 4(6):973-80. PubMed ID: 17181414
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of newer macrolides.
    Nightingale CH.
    Pediatr Infect Dis J; 1997 Apr 15; 16(4):438-43. PubMed ID: 9109156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.